These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 25063295)

  • 61. CRISPR-Cas and restriction-modification systems are compatible and increase phage resistance.
    Dupuis MÈ; Villion M; Magadán AH; Moineau S
    Nat Commun; 2013; 4():2087. PubMed ID: 23820428
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
    Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
    mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Exploitation of the Cooperative Behaviors of Anti-CRISPR Phages.
    Chevallereau A; Meaden S; Fradet O; Landsberger M; Maestri A; Biswas A; Gandon S; van Houte S; Westra ER
    Cell Host Microbe; 2020 Feb; 27(2):189-198.e6. PubMed ID: 31901522
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system.
    Bondy-Denomy J; Pawluk A; Maxwell KL; Davidson AR
    Nature; 2013 Jan; 493(7432):429-32. PubMed ID: 23242138
    [TBL] [Abstract][Full Text] [Related]  

  • 65. On the Origin of CRISPR-Cas Technology: From Prokaryotes to Mammals.
    Mojica FJM; Montoliu L
    Trends Microbiol; 2016 Oct; 24(10):811-820. PubMed ID: 27401123
    [TBL] [Abstract][Full Text] [Related]  

  • 66. One-step high-efficiency CRISPR/Cas9-mediated genome editing in Streptomyces.
    Huang H; Zheng G; Jiang W; Hu H; Lu Y
    Acta Biochim Biophys Sin (Shanghai); 2015 Apr; 47(4):231-43. PubMed ID: 25739462
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Characterization of a novel lytic bacteriophage from an industrial Escherichia coli fermentation process and elimination of virulence using a heterologous CRISPR-Cas9 system.
    Halter MC; Zahn JA
    J Ind Microbiol Biotechnol; 2018 Mar; 45(3):153-163. PubMed ID: 29411201
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
    Xu R; Wei P; Yang J
    Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Anti-CRISPR Story: A Battle for Survival.
    Maxwell KL
    Mol Cell; 2017 Oct; 68(1):8-14. PubMed ID: 28985512
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Characterization of the cro-ori region of the Streptococcus thermophilus virulent bacteriophage DT1.
    Lamothe G; Lévesque C; Bissonnette F; Cochu A; Vadeboncoeur C; Frenette M; Duplessis M; Tremblay D; Moineau S
    Appl Environ Microbiol; 2005 Mar; 71(3):1237-46. PubMed ID: 15746324
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Analysis of the CRISPR-Cas system in bacteriophages active on epidemic strains of Vibrio cholerae in Bangladesh.
    Naser IB; Hoque MM; Nahid MA; Tareq TM; Rocky MK; Faruque SM
    Sci Rep; 2017 Nov; 7(1):14880. PubMed ID: 29093571
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Stumbling across the Same Phage: Comparative Genomics of Widespread Temperate Phages Infecting the Fish Pathogen Vibrio anguillarum.
    Kalatzis PG; Rørbo NI; Castillo D; Mauritzen JJ; Jørgensen J; Kokkari C; Zhang F; Katharios P; Middelboe M
    Viruses; 2017 May; 9(5):. PubMed ID: 28531104
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CRISPR immunity drives rapid phage genome evolution in Streptococcus thermophilus.
    Paez-Espino D; Sharon I; Morovic W; Stahl B; Thomas BC; Barrangou R; Banfield JF
    mBio; 2015 Apr; 6(2):. PubMed ID: 25900652
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparative Analysis of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) of Streptococcus thermophilus St-I and its Bacteriophage-Insensitive Mutants (BIM) Derivatives.
    Li W; Bian X; Evivie SE; Huo GC
    Curr Microbiol; 2016 Sep; 73(3):393-400. PubMed ID: 27378131
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Extending CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus Clostridium.
    Bruder MR; Pyne ME; Moo-Young M; Chung DA; Chou CP
    Appl Environ Microbiol; 2016 Oct; 82(20):6109-6119. PubMed ID: 27496775
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CRISPR-Cas system: a powerful tool for genome engineering.
    Liu L; Fan XD
    Plant Mol Biol; 2014 Jun; 85(3):209-18. PubMed ID: 24639266
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bacteriophage genome engineering with CRISPR-Cas13a.
    Guan J; Oromí-Bosch A; Mendoza SD; Karambelkar S; Berry JD; Bondy-Denomy J
    Nat Microbiol; 2022 Dec; 7(12):1956-1966. PubMed ID: 36316452
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sequences spanning the leader-repeat junction mediate CRISPR adaptation to phage in Streptococcus thermophilus.
    Wei Y; Chesne MT; Terns RM; Terns MP
    Nucleic Acids Res; 2015 Feb; 43(3):1749-58. PubMed ID: 25589547
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
    Hryhorowicz M; Lipiński D; Zeyland J; Słomski R
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):233-240. PubMed ID: 27699445
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characterization of the lysogeny DNA module from the temperate Streptococcus thermophilus bacteriophage phi Sfi21.
    Bruttin A; Desiere F; Lucchini S; Foley S; Brüssow H
    Virology; 1997 Jun; 233(1):136-48. PubMed ID: 9201223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.